Pulse Biosciences announced a strategic realignment that places the nPulse Cardiac Catheter Ablation System at the center of its development and commercialization plans. The shift follows a European feasibility study involving more than 150 patients, which the company described as a “definitive message” about the platform’s performance.
The feasibility data are striking: 100 % procedural success at 6 months (75 of 75 evaluable patients) and 96 % sustained success at 12 months (45 of 47 patients). The results demonstrate the advantages of the company’s nanosecond pulsed‑field ablation (nsPFA) technology, which delivers rapid, tissue‑selective lesions without the thermal injury associated with microsecond‑based systems.
Pulse is now focusing on the atrial fibrillation market, where nsPFA offers faster, safer, and more durable ablations than existing solutions. Boston Scientific and Medtronic dominate the space, but the company believes its first‑in‑class technology can capture a meaningful share of the market.
Management emphasized the significance of the data. Bob Duggan said, “The European feasibility data from over 150 patients sends a definitive message. The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this extraordinary opportunity.” Paul LaViolette added, “We are thrilled to be allocating additional resources to the vast potential of our catheter‑based EP program. We are fortifying a program that has already shown the potential to be first‑in‑class and best‑in‑class.”
Financially, Pulse has faced negative revenue growth, a negative gross margin, and net losses. For Q4 2025 the GAAP net loss was $17.4 million versus $19.4 million a year earlier, and the non‑GAAP net loss was $12.2 million versus $10.4 million. The full‑year 2025 GAAP net loss was $72.8 million compared with $53.6 million, while the non‑GAAP net loss was $50.8 million versus $36.9 million. Cash and cash equivalents stood at $80.7 million, and the company has a shelf registration for up to $200 million to support future financing needs. Pulse continues to advance other programs, including the Surgical Clamp IDE and the Vybrance Percutaneous Electrode System, and has a research collaboration with MD Anderson Cancer Center.
Regulatory and commercial milestones are also part of the realignment. Pulse plans to submit a CE Mark application in the second half of 2026, with approval expected in 2027, and it has received FDA approval for an Investigational Device Exemption to initiate the NANOPULSE‑AF study for paroxysmal atrial fibrillation. The company’s goal is to commence and complete IDE enrollment in 2026 and to accelerate the catheter’s path to regulatory approval and market adoption, thereby unlocking new revenue streams and extending its runway.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.